Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000639584 | SCV000761161 | likely benign | Landau-Kleffner syndrome | 2024-01-15 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV001816592 | SCV002070531 | uncertain significance | not specified | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002369668 | SCV002684331 | uncertain significance | Inborn genetic diseases | 2017-06-29 | criteria provided, single submitter | clinical testing | The p.G295S variant (also known as c.883G>A), located in coding exon 2 of the GRIN2A gene, results from a G to A substitution at nucleotide position 883. The glycine at codon 295 is replaced by serine, an amino acid with similar properties. This alteration has been reported in an individual with Rolandric epilepsy, however the inheritance of the alteration could not be determined (Lesca G et al. Nat. Genet., 2013 Sep;45:1061-6; Burnashev N et al. Curr. Opin. Pharmacol., 2015 Feb;20:73-82). In addition, functional studies performed to determine the impact of the alteration on the receptor expression and activation showed no significant difference from the wild-type (Serraz B et al. Neuropharmacol., 2016 Oct;109:196-204). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. . |